Welcome to our dedicated page for Spyre Therapeutics SEC filings (Ticker: SYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Investors trying to untangle Spyre Therapeutics’ biotech disclosures often wade through pages of immunology jargon, multi-year R&D accruals, and milestone-based licensing clauses. Locating clinical-trial costs in a 10-K or confirming a sudden Form 8-K study halt can take hours, and tracking executive share sales before financing rounds is even harder. That complexity is why so many searches start with natural questions like “where can I find Spyre Therapeutics quarterly earnings report 10-Q filing?” or “Spyre Therapeutics insider trading Form 4 transactions.” We built this page to answer those questions immediately.
With Stock Titan’s AI-powered analysis, every Spyre Therapeutics SEC filing is explained simply. Our algorithms parse the latest 10-K annual report, highlight key pipeline disclosures, and surface cash-burn trends, giving you a “Spyre Therapeutics annual report 10-K simplified” view in seconds. Real-time alerts flag “Spyre Therapeutics Form 4 insider transactions” the moment they hit EDGAR, while concise summaries break down each “Spyre Therapeutics 8-K material events explained” notice. Whether you need “Spyre Therapeutics proxy statement executive compensation” tables, or an “earnings report filing analysis” of quarterly R&D spend, the information arrives ready to use.
Every filing is linked to what matters for this clinical-stage IBD innovator. Compare α4β7 antibody trial results across quarters, monitor financing covenants that could shift run-way projections, or study “understanding Spyre Therapeutics SEC documents with AI” case notes that connect pipeline milestones to market valuation. Our coverage spans all forms—10-K, 10-Q, 8-K, S-1, and the executive stock transactions Form 4 feed—updated in real time. Spend less time decoding dense biology and more time making informed decisions with complete, investor-ready context.
Spyre Therapeutics CFO Scott L. Burrows reported a sell-to-cover transaction tied to the settlement of restricted stock units. The filing shows 18,428 shares of common stock were sold at a weighted average price reported near $16.26, generated to satisfy tax withholding obligations arising from the settlement of 33,738 RSUs. Following the sale, the reporting person beneficially owns 97,994 shares outright.
The report also discloses an additional 67,476 RSUs that remain outstanding; those RSUs vest in two equal installments on September 1, 2026 and September 1, 2027, subject to continued employment. The transaction is described as non-discretionary and solely for tax withholding.
FAQ
What is the current stock price of Spyre Therapeutics (SYRE)?
What is the market cap of Spyre Therapeutics (SYRE)?
